These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28272913)

  • 1. Phase I Study of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma.
    Ishizaki M; Kaibori M; Matsui K; Ikeda H; Yoshida K; Okazaki K; Kariya S; Tanigawa N; Nakatake R; Matsushima H; Sakaguchi T; Kon M
    Cancer Invest; 2017 Apr; 35(4):271-276. PubMed ID: 28272913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting.
    Kondo M; Morimoto M; Ishii T; Nozaki A; Fukuda H; Numata K; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Shibuya A; Okuse C; Suzuki M; Sakamaki K; Morita S; Maeda S; Tanaka K
    J Dig Dis; 2015 Mar; 16(3):143-51. PubMed ID: 25495751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
    Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib plus cisplatin for hepatocellular carcinoma.
    Brower V
    Lancet Oncol; 2016 Oct; 17(10):e424. PubMed ID: 27617663
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
    J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma.
    Hagihara A; Ikeda M; Ueno H; Morizane C; Kondo S; Nakachi K; Mitsunaga S; Shimizu S; Kojima Y; Suzuki E; Katayama K; Imanaka K; Tamai C; Inaba Y; Sato Y; Kato M; Okusaka T
    Cancer Sci; 2014 Mar; 105(3):354-8. PubMed ID: 24438504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial.
    Ikeda M; Shimizu S; Sato T; Morimoto M; Kojima Y; Inaba Y; Hagihara A; Kudo M; Nakamori S; Kaneko S; Sugimoto R; Tahara T; Ohmura T; Yasui K; Sato K; Ishii H; Furuse J; Okusaka T
    Ann Oncol; 2016 Nov; 27(11):2090-2096. PubMed ID: 27573564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot Study of Intrahepatic Artery Chemotherapy in Combination with Sorafenib in Hepatocellular Carcinoma.
    Dinh VY; Bhatia S; Narayanan G; Yrizarry J; Savaraj N; O'Brien C; Martin P; Feun L
    Anticancer Res; 2016 Jul; 36(7):3555-63. PubMed ID: 27354623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.
    He MK; Zou RH; Li QJ; Zhou ZG; Shen JX; Zhang YF; Yu ZS; Xu L; Shi M
    Cardiovasc Intervent Radiol; 2018 May; 41(5):734-743. PubMed ID: 29327075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
    Miyaki D; Aikata H; Kan H; Fujino H; Urabe A; Masaki K; Fukuhara T; Kobayashi T; Naeshiro N; Nakahara T; Kawaoka T; Hiramatsu A; Takahashi S; Ishikawa M; Kakizawa H; Awai K; Chayama K
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1834-41. PubMed ID: 23808713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus--a pilot study].
    Ishizaki M; Kaibori M; Matsui K; Yanagimoto Y; Nakatake R; Kwon AH
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2679-82. PubMed ID: 21224678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.
    Shiozawa K; Watanabe M; Ikehara T; Kogame M; Matsui T; Okano N; Kikuchi Y; Nagai H; Ishii K; Makino H; Igarashi Y; Sumino Y
    Hepatogastroenterology; 2014 Jun; 61(132):885-91. PubMed ID: 26158136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combination Chemotherapy Using Sorafenib and Hepatic Arterial Infusion with a Fine-Powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis--A Case Report].
    Tsukamoto T; Kanazawa A; Shimizu S; Murata A; Sakae M; Kurihara S; Tashima T; Deguchi S; Nakai T; Kawasaki Y; Kioka K
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1878-80. PubMed ID: 26805203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma].
    Yamashita T; Kaneko S
    Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1335-45. PubMed ID: 22863956
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
    Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
    J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Song DS; Song MJ; Bae SH; Chung WJ; Jang JY; Kim YS; Lee SH; Park JY; Yim HJ; Cho SB; Park SY; Yang JM
    J Gastroenterol; 2015 Apr; 50(4):445-54. PubMed ID: 25027973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma.
    Poggi G; Montagna B; Melchiorre F; Quaretti P; Delmonte A; Riccardi A; Tagliaferri B; Sottotetti F; Di Cesare P; Stella MG; Villani L; Zorzetto M; Greco G; Cornalba G; Bernardo G
    Anticancer Res; 2011 Nov; 31(11):3927-33. PubMed ID: 22110221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial.
    Kamimura K; Suda T; Yokoo T; Kamimura H; Kanefuji T; Tsuchiya A; Takamura M; Kawai H; Waguri N; Yamagiwa S; Terai S
    BMC Cancer; 2017 May; 17(1):322. PubMed ID: 28490356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
    Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
    Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement.
    Tsimberidou AM; Moulder S; Fu S; Wen S; Naing A; Bedikian AY; Daring S; Uehara C; Ng C; Wallace M; Camacho L; Kurzrock R
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1087-93. PubMed ID: 20204368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.